Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Genetic differences in drug disposition

D G May1

  • 1Department of Pediatrics, Wayne State University, Children's Hospital of Michigan, Detroit 48201.

Journal of Clinical Pharmacology
|September 1, 1994
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Frequency distribution of dapsone N-hydroxylase, a putative probe for P4503A4 activity, in a white population.

Clinical pharmacology and therapeutics·1994
Same author

Cimetidine-carbaryl interaction in humans: evidence for an active metabolite of carbaryl.

The Journal of pharmacology and experimental therapeutics·1992
Same author

The disposition of dapsone in cirrhosis.

Clinical pharmacology and therapeutics·1992
Same author

The contribution of N-hydroxylation and acetylation to dapsone pharmacokinetics in normal subjects.

Clinical pharmacology and therapeutics·1990
Same author

Scleroderma is associated with differences in individual routes of drug metabolism: a study with dapsone, debrisoquin, and mephenytoin.

Clinical pharmacology and therapeutics·1990
Same author

Carbaryl metabolism is inhibited by cimetidine in the isolated perfused rat liver and in man.

Journal of toxicology. Clinical toxicology·1988
Same journal

Human Disposition, Metabolism, and Excretion of Sevasemten (EDG-5506), a Selective Modulator of Fast Myosin in Healthy Volunteers.

Journal of clinical pharmacology·2026
Same journal

New Insights into Genetic Polymorphisms Influencing the Therapeutic Efficacy and Toxicity of Rivaroxaban.

Journal of clinical pharmacology·2026
Same journal

Physiologically Based Pharmacokinetic Modeling to Predict the Pharmacokinetics of Sacubitril/Valsartan in the Elderly with Renal or Hepatic Impairment Population.

Journal of clinical pharmacology·2026
Same journal

The Journal of Clinical Pharmacology: 65 Years of History.

Journal of clinical pharmacology·2026
Same journal

Decoupling CAR-T Expansion, Conversion, and Decay Timing: Physiologically Aligned Semi-Mechanistic Modeling With Smooth Gating and a Cauchy Likelihood Residual Model.

Journal of clinical pharmacology·2026
Same journal

Mind the Gap: Unraveling the Pharmacokinetic Variability of Δ9-Tetrahydrocannabinol (THC).

Journal of clinical pharmacology·2026
See all related articles

Genetic variations in drug-metabolizing enzymes influence drug response and toxicity. Understanding these genetic polymorphisms can personalize medicine and reduce disease risk from environmental factors.

Area of Science:

  • Pharmacogenomics
  • Biochemistry
  • Toxicology

Background:

  • Genetic polymorphisms in drug-metabolizing enzymes are well-established.
  • These variations lead to significant inter-individual differences in drug response.

Purpose of the Study:

  • To review the molecular mechanisms, development, and clinical relevance of genetic variations in key drug-metabolizing enzymes.
  • To discuss implications for drug efficacy, toxicity, and susceptibility to environmental agents.

Main Methods:

  • Literature review focusing on polymorphic enzymes like N-acetyl transferase, cytochromes P450 (CYP2D6, CYP2C), and conjugation pathways.
  • Analysis of genetic factors influencing enzyme activity and their impact on xenobiotic metabolism.

Main Results:

Related Experiment Videos

  • Detailed examination of well-characterized polymorphic enzymes (e.g., NAT, CYP2D6, CYP2C).
  • Discussion of emerging research on other Phase I and Phase II polymorphic pathways (e.g., glutathione S-transferases, methyltransferases, alcohol/acetaldehyde oxidation).
  • Evidence linking genetic enzyme differences to drug disposition, efficacy, toxicity, and susceptibility to carcinogens/teratogens.

Conclusions:

  • Genetic factors are critical determinants of drug metabolism and clinical outcomes.
  • Knowledge of pharmacogenetics can guide individualized medical therapy.
  • Understanding these variations may help minimize xenobiotic-induced diseases.